Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100772953> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W3100772953 abstract "Introduction: Several clinical phenotypes have been described in patients with heart failure with preserved ejection fraction (HFpEF). This heterogeneity may explain why no therapies have improved outcomes in clinical trials of HFpEF patients. In a secondary analysis of TOPCAT, the authors discovered improved mortality in female HFpEF patients treated with spironolactone. The objective of this study was to determine if outcomes for spironolactone in women with HFpEF varied by female-specific phenotypes. Methods: Using 10 clinical variables, a latent class analysis (LCA) of 5196 female patients from 7 clinical trials (BEST, IPRESERVE, MOCHA, NEAT-HFpEF, RELAX, TOPCAT, and SOLVD) was used to identify phenotypes across the LVEF spectrum, which included 3 distinct phenotypes of HFpEF patients. A post-hoc analysis of TOPCAT was completed to analyze the outcomes of spironolactone versus placebo by female phenotype. The outcomes were cardiovascular (CV) mortality, heart failure (HF) hospitalizations, all-cause mortality, and CV hospitalizations. Results: Table 1 shows characteristics of 3 female HFpEF phenotypes: phenotype 1 “aging hypertensive”, phenotype 2 “younger hypertensive”, and phenotype 3 “obesity phenotype”. 887 female patients from the TOPCAT trial were analyzed according to these phenotypes. Of these, only phenotype 1 showed a benefit of spironolactone therapy compared to placebo with regards to the primary outcome of CV mortality and HF hospitalizations (20.8% vs 30.2%, p<0.05) as well as the composite of all-cause mortality and CV hospitalizations (41.1% vs 51.3%, p<0.05). Conclusion: Older, hypertensive women with HFpEF show a significant reduction in CV mortality and HF hospitalizations when treated with spironolactone vs. placebo, whereas other women did not. Prior studies show that this phenotype is often associated with a higher mortality, thus spironolactone may be particularly important in this patient population." @default.
- W3100772953 created "2020-11-23" @default.
- W3100772953 creator A5028982390 @default.
- W3100772953 creator A5071570302 @default.
- W3100772953 date "2020-11-17" @default.
- W3100772953 modified "2023-10-17" @default.
- W3100772953 title "Abstract 15229: Clinical Phenotype Differences in Outcomes and Responses of Spironolactone in Heart Failure With Preserved Ejection Fraction" @default.
- W3100772953 doi "https://doi.org/10.1161/circ.142.suppl_3.15229" @default.
- W3100772953 hasPublicationYear "2020" @default.
- W3100772953 type Work @default.
- W3100772953 sameAs 3100772953 @default.
- W3100772953 citedByCount "0" @default.
- W3100772953 crossrefType "journal-article" @default.
- W3100772953 hasAuthorship W3100772953A5028982390 @default.
- W3100772953 hasAuthorship W3100772953A5071570302 @default.
- W3100772953 hasConcept C104317684 @default.
- W3100772953 hasConcept C126322002 @default.
- W3100772953 hasConcept C127716648 @default.
- W3100772953 hasConcept C142724271 @default.
- W3100772953 hasConcept C164705383 @default.
- W3100772953 hasConcept C185592680 @default.
- W3100772953 hasConcept C204787440 @default.
- W3100772953 hasConcept C27081682 @default.
- W3100772953 hasConcept C2776379505 @default.
- W3100772953 hasConcept C2777099384 @default.
- W3100772953 hasConcept C2778198053 @default.
- W3100772953 hasConcept C3020646490 @default.
- W3100772953 hasConcept C535046627 @default.
- W3100772953 hasConcept C55493867 @default.
- W3100772953 hasConcept C67761136 @default.
- W3100772953 hasConcept C71924100 @default.
- W3100772953 hasConcept C78085059 @default.
- W3100772953 hasConceptScore W3100772953C104317684 @default.
- W3100772953 hasConceptScore W3100772953C126322002 @default.
- W3100772953 hasConceptScore W3100772953C127716648 @default.
- W3100772953 hasConceptScore W3100772953C142724271 @default.
- W3100772953 hasConceptScore W3100772953C164705383 @default.
- W3100772953 hasConceptScore W3100772953C185592680 @default.
- W3100772953 hasConceptScore W3100772953C204787440 @default.
- W3100772953 hasConceptScore W3100772953C27081682 @default.
- W3100772953 hasConceptScore W3100772953C2776379505 @default.
- W3100772953 hasConceptScore W3100772953C2777099384 @default.
- W3100772953 hasConceptScore W3100772953C2778198053 @default.
- W3100772953 hasConceptScore W3100772953C3020646490 @default.
- W3100772953 hasConceptScore W3100772953C535046627 @default.
- W3100772953 hasConceptScore W3100772953C55493867 @default.
- W3100772953 hasConceptScore W3100772953C67761136 @default.
- W3100772953 hasConceptScore W3100772953C71924100 @default.
- W3100772953 hasConceptScore W3100772953C78085059 @default.
- W3100772953 hasIssue "Suppl_3" @default.
- W3100772953 hasLocation W31007729531 @default.
- W3100772953 hasOpenAccess W3100772953 @default.
- W3100772953 hasPrimaryLocation W31007729531 @default.
- W3100772953 hasRelatedWork W1883738259 @default.
- W3100772953 hasRelatedWork W2051712573 @default.
- W3100772953 hasRelatedWork W2061321770 @default.
- W3100772953 hasRelatedWork W2077083067 @default.
- W3100772953 hasRelatedWork W2187526770 @default.
- W3100772953 hasRelatedWork W2334396920 @default.
- W3100772953 hasRelatedWork W2789205885 @default.
- W3100772953 hasRelatedWork W2965474825 @default.
- W3100772953 hasRelatedWork W3033076790 @default.
- W3100772953 hasRelatedWork W4200030969 @default.
- W3100772953 hasVolume "142" @default.
- W3100772953 isParatext "false" @default.
- W3100772953 isRetracted "false" @default.
- W3100772953 magId "3100772953" @default.
- W3100772953 workType "article" @default.